Shattuck Labs

Founded with a mission to revolutionize cancer and autoimmune disease treatment, Shattuck Labs is a clinical-stage biotechnology company. The company's core vision is to develop innovative bifunctional fusion proteins using their proprietary Agonist Redirected Checkpoint (ARC®) technology. This technology uniquely targets and unlocks the TNFr superfamily while simultaneously blocking immune checkpoints, addressing fundamental structural limitations of other modalities. Shattuck Labs focuses on creating a new class of biologic medicines that offer novel therapeutic solutions for patients with cancer and autoimmune diseases.

Shattuck Labs has attracted notable investors and scientific minds in the biotech industry, contributing to its rapid advancement and recognition. The company has achieved significant milestones, including the successful development of modular technology that allows for the efficient creation of thousands of therapeutic candidates. Shattuck Labs' innovative approach and groundbreaking research have positioned it as a leader in the biotechnology sector, making a substantial impact on the future of cancer and autoimmune disease treatment.